BDNF rs6265 polymorphism is not associated with the occurrence of overactive bladder and its response to intradetrusor injection of botulinum neurotoxin type A in female patients

Reports suggest increased urinary excretion of Brain-Derived Neurotrophic Factor in patients with Overactive Bladder (OAB). The rs6265 (c.196G > A, p.Val66Met) polymorphism in the BDNF gene was previously associated with impaired secretion of this neurotrophin. The aims of the present study were to analyze the possible association of the BDNF: rs6265 polymorphism with OAB risk and with the response to a single intradetrusor injection of botulinum neurotoxin type A (BoNT/A) in female patients. The study group comprised 160 OAB females, and the control group comprised 359 healthy females. Urodynamic parameters, frequencies of OAB symptoms, and scores from ICIQ-OAB and ICIQ-LUTS-QoL questionnaires were recorded before BoNT/A injection and six months after. Genotyping of BDNF: rs6265 polymorphism was performed using TaqMan real-time polymerase chain reaction. No statistically significant differences in the distribution of BDNF genotypes or alleles between OAB patients and healthy controls were found. No significant differences among OAB subjects regarding BDNF polymorphism were found in terms of clinical symptoms, scores of both questionnaires, and urodynamic parameters. These results do not support the hypothesis that BDNF: rs6265 polymorphism in Polish females with OAB is associated with susceptibility to this condition and with response to BoNT/A treatment.